The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3387-3398

  Wietrzyk, Joanna ^a   Nevozhay, Dmitry ^a,b   Filip, Beata ^a   Milczarek, Magdalena ^a   Kutner, Andrzej ^c  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b Kopvillem Institute of Medical Physics   (Russian Federation)

^c INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Anticancer activity; Combined treatment; Cytostatic; Toxicity; Vitamin D analogs

Indexed keywords

CALCIPOTRIOL; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; PRI 2191; PRI 2201; PRI 2202; PRI 2205; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; LEWIS CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CALCIUM; CARCINOMA, LEWIS LUNG; CISPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; VITAMIN D;

EID: 35348963580     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Opolski A Wietrzyk J, Chrobak A, Marcinkowska E, Wojdat E, Kutner A and Radzikowski C: Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res 19: 5217-5222, 1999.
2. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 2: 475-480, 1991.
3. Norman AW, Mizwicki MT and Okamura WH: Ligand structure-function relationships in the vitamin D endocrine system from the perspective of drug development (including cancer treatment). Recent Results Cancer Res 164: 55-82, 2003.
4. 3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 89: 117-124, 1995.
5. 3 and retinoic acid. Exp Cell Res 249: 279-290, 1999.
6. Asou H, Koike M, Elstner E, Cambell M, Le J, Uskokovic MR, Kamada N and Koeffler HP: 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998.
7. Opolski A, Wietrzyk J, Siwinska A, Marcinkowska E, Chrobak A Radzikowski C and Kutner A: Biological activity in vitro of side-chain modified analogues of calcitriol. Curr Pharm Des 6: 755-765, 2000.
8. 3. J Steroid Biochem Mol Biol 67: 71-78, 1998.
9. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 1: 410-415, 2002.
10. Elias J, Marian B, Edling C, Lachmann B, Noe CR, Rolf SH and Schuster I: Induction of apoptosis by vitamin D metabolites and analogs in a glioma cell line. Recent Results Cancer Res 164: 319-332, 2003.
11. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA and Albert DM: Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 36: 83-87, 1995.
12. 3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 41: 37-45, 1995.
13. 2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res 25: 235-241, 2005.
14. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26: 1044-1054, 2005.
15. Lamprecht SA and Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3: 601-614, 2003.
16. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K and Narvaez CJ: Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 133: 2425S-2433S, 2003.
17. 5, a synthetic analog of Vitamin D. Mutat Res 523-524: 253-264, 2003.
18. Nakagawa K, Kawaura A, Kato S, Takeda E and Okano T: 1 alpha, 25-dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26: 429-440, 2005.
19. Krishnan AV, Peehl DM and Feldman D: The role of vitamin D in prostate cancer. Recent Results Cancer Res 164: 205-221, 2003.
20. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW and Trump DL: A Phase I trial of calcitriol (1, 25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345, 1999.
21. Peehl DM, Krishnan AV and Feldman D: Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr 133: 2461S-2469S, 2003.
22. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach HJ, Steward WP, Skov T, Burcharth F and Evans TR: A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89: 252-257, 2003.
23. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS and Trump DL: Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72: 648-659, 2002.
24. Beer TM, Hough KM, Garzotto M, Lowe BA and Henner WD: Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28: 49-55, 2001.
25. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG and Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41: 1164-1169, 2005.
26. 3 receptor promoter in breast cancer cells is mediated through Sp1 sites. Mol Cell Endocrinol 230: 59-68, 2005.
27. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60: 2673-2679, 2000.
28. Chodynski M, Wietrzyk J, Marcinkowska E, Opolski A, Szelejewski W and Kutner A: Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a- homo-1, 25-dihydroxyergocalciferol and congeners. Steroids 67: 789-798, 2002.
29. 3 compounds in combination with cytostatics. Anticancer Res 25: 2235-2240, 2005.
30. Siwinska A, Opolski A, Chrobak A, Wietrzyk J, Wojdat E, Kutner A, Szelejewski W and Radzikowski C: Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res 21: 1925-1929, 2001.
31. Pelczynska M, Switalska M, Maciejewska M, Jaroszewicz I, Kutner A and Opolski A: Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 26: 2701-2705, 2006.
32. 3 (PRI-2191). Steroids 69: 629-635, 2004.
33. Marcinkowska E and Kutner A: Side-chain modified vitamin D analogs require activation of both PI 3-K and erk1, 2 signal transduction pathways to induce differentiation of human promyelocytic leukemia cells. Acta Biochim Pol 49: 393-406, 2002.
34. 3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853, 1991.
35. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999.
36. Chrobak A Radzikowski C and Opolski A: Side-chain-modified analogs of calcitriol cause resistance of human HL-60 promyelocytic leukemia cells to drug-induced apoptosis. Steroids 70: 19-27, 2005.
37. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991.
38. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E and Ikeda K: Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53: 2534-2537, 1993.
39. Beer TM, Lemmon D, Lowe BA and Henner WD: High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 97: 1217-1224, 2003.
40. 3. In: Vitamin D: Biochemical, Chemical and Clinical Aspects Related to Calcium Metabolism. Norman AW, Schaefer K, Coburn JW, De Luca HF, Fraser D, Grigoleit HG and van Herrath D (eds.). Berlin-New York, Walter de Gruyter, pp. 587-589, 1977.
41. Bouillon R, Okamura WH and Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995.
42. 3. Anticancer Drugs 18: 447-457, 2007.
43. Kutner A: Convergent synthesis of vitamin D analogs [in Polish] (Konwergentna synteza analogow witamin D). Przemysl Chemiczny 85: 322-329, 2006.
44. Hershberger PA Yu WD, Modzelewski RA, Rueger RM, Johnson CS and Trump DL: Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7: 1043-1051, 2001.
45. 3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1: 821-829, 2002.
46. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5: 695-703, 1999.
47. Posner GH, Crawford KR, Peleg S, Welsh JE, Romu S, Gewirtz DA, Gupta MS, Dolan P and Kensler TW: A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin. Bioorg Med Chem 9: 2365-2371, 2001.
48. Danilenko M and Studzinski GP: Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. Exp Cell Res 298: 339-358, 2004.
49. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL and Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997.
50. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J and Anderson RL: A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17: 163-170, 1999.
51. Shaker JL, Redlin KC, Warren GV and Findling JW: Case report: hypercalcemia with inappropriate 1,25-dihydroxyvitamin D in Wegener's granulomatosis. Am J Med Sci 308: 115-118, 1994.
52. Bosch X, Lopez-Soto A, Morello A, Olmo A and Urbano-Marquez A: Vitamin D metabolite-mediated hypercalcemia in Wegener's granulomatosis. Mayo Clin Proc 72: 440-444, 1997.
53. Yagisawa K, Aiba A, Momoi A, Tsukada N, Nikkuni K, Aoki S and Aizawa Y: High-dose cyclophosphamide as an effective therapy for a patient with refractory multiple myeloma relapsing after autologous stem cell transplantation. Intern Med 44: 471-475, 2005.
54. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD and Johnson CS: Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90: 519-526, 2004.
55. Kawai Y, Nakao T, Kunimura N, Kohda Y and Gemba M: Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci 100: 65-72, 2006.
56. Price PA, Buckley JR and Williamson MK: The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131: 2910-2915, 2001.